site meter

search

Google

result

Tuesday, May 4, 2010

RNA appears to play a big role in the development of idiopathic pulmonary fibrosis

Contact: Anita Srikameswaran
SrikamAV@upmc.edu
412-578-9193
Public release date: 29-Apr-2010

 
PITTSBURGH, April 29 – A small piece of RNA appears to play a big role in the development of idiopathic pulmonary fibrosis (IPF), according to lung disease researchers at the University of Pittsburgh School of Medicine. Their study, which is the first to examine microRNAs in the disease, is available online in the American Journal of Respiratory and Critical Care Medicine.

MicroRNAs are short strands of genetic material that are involved in regulating the expression, or activity, of genes, explained senior author Naftali Kaminski, M.D., associate professor of medicine, computational biology and pathology, and director of the Dorothy P. and Richard P. Simmons Center for Interstitial Lung Diseases at the University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center. They are a new family of RNA molecules that are thought to be factors in embryonic development, multiple cancers and chronic heart failure.

"Our research now indicates that microRNA changes also contribute to IPF," Dr. Kaminski said. "We have identified an entirely new molecular mechanism for the disease, which gives us new ideas about how to treat it."

The researchers assessed microRNA profiles in samples of healthy lung tissue and samples of tissue affected by IPF, which is a chronic, progressive and usually lethal disease of lung scarring that affects more than 100,000 Americans and leads to 15,000 deaths annually.

"Ten percent of the microRNAs were different between IPF and control lungs," said Kusum Pandit, Ph.D., the study's lead author and a postdoctoral researcher in Dr. Kaminski's lab. "The changes were very impressive."

The researchers particularly noted a diminished amount of a microRNA called let-7d and examined it more closely. They found almost no expression of let-7d in the fibrotic, or scarred, areas of 40 IPF lung samples, whereas it was abundant in 20 healthy samples used for comparison. Further experimentation showed them that let-7d is inhibited by the cytokine TGF-beta, a signaling protein that promotes the development of fibrosis through several biological pathways.

In another experiment, the researchers made an antagonist that inhibits let-7d and administered it to several mice through their windpipes for a few days. When examined soon after, the lungs of the mice looked very much like what is seen in patients with early lung fibrosis.

"These results suggest that by increasing let-7d in the lung, we may be able to slow down or even prevent lung fibrosis," Dr. Kaminski said. "Our next challenge is to develop methods that will allow us to safely do that so we can test its therapeutic value."

########################################################

Co-authors include several other researchers from the Simmons Center, the University of Pittsburgh School of Medicine and the Graduate School of Public Health; Democritus University of Thrace and University Hospital of Alexandroupolis, Greece; Instituto Nacional de Enfermedades Respiratorias, Mexico; Universidad Nacional Autonoma de Mexico, Mexico; and Comprehensive Pneumonology Center, Germany.

The study was funded by grants from the National Institutes of Health, the Dorothy P. and Richard P. Simmons Endowed Chair for Pulmonary Research and Universidad Nacional Autonoma de Mexico.

About the the University of Pittsburgh School of Medicine

As one of the nation's leading academic centers for biomedical research, the University of Pittsburgh School of Medicine integrates advanced technology with basic science across a broad range of disciplines in a continuous quest to harness the power of new knowledge and improve the human condition. Driven mainly by the School of Medicine and its affiliates, Pitt has ranked among the top 10 recipients of funding from the National Institutes of Health since 1997 and now ranks fifth in the nation, according to preliminary data for fiscal year 2008. Likewise, the School of Medicine is equally committed to advancing the quality and strength of its medical and graduate education programs, for which it is recognized as an innovative leader, and to training highly skilled, compassionate clinicians and creative scientists well-equipped to engage in world-class research. The School of Medicine is the academic partner of UPMC, which has collaborated with the University to raise the standard of medical excellence in Pittsburgh and to position health care as a driving force behind the region's economy. For more information about the School of Medicine, see http://www.medschool.pitt.edu/

Published in

1 comment:

Thani Harith al Mahrouki said...

Thank you so much. I visited your blog. It looks professional and the diagrams are so attractive!

Popular Posts

Followers

My Travel Map

تأخير الصلاة